The aim of this ESC Guideline is to help health professionals manage people with heart
failure (HF) according to the best available evidence. Fortunately, we now have a wealth of …

In this update of the Canadian Cardiovascular Society heart failure (HF) guidelines, we
provide comprehensive recommendations and practical tips for the pharmacologic …

The sodium–glucose cotransporter 2 inhibitor empagliflozin reduces the risk of
cardiovascular death or heart failure hospitalization in patients with chronic heart failure, but …

Abstract Document Reviewers: Rudolf A. de Boer (CPG Review Coordinator)(Netherlands),
P. Christian Schulze (CPG Review Coordinator)(Germany), Magdy Abdelhamid (Egypt) …

Background Patients with acute heart failure are frequently or systematically hospitalized,
often because the risk of adverse events is uncertain and the options for rapid follow-up are …

Importance Although furosemide is the most commonly used loop diuretic in patients with
heart failure, some studies suggest a potential benefit for torsemide. Objective To determine …

Heart failure (HF) has been recognized as a common complication of diabetes, with a
prevalence of up to 22% in individuals with diabetes and increasing incidence rates. Data …

Heart failure (HF) is a progressive disease characterized by variable durations of
symptomatic stability often punctuated by episodes of worsening despite continued therapy …

Background: The impact of hospital readmission reduction program (HRRP) on heart failure
(HF) outcomes has been debated. Limited data exist regarding trends of HF readmission …

Background: Guidelines recommend that patients with heart failure with reduced ejection
fraction (HFrEF) have medical therapy titrated to target doses derived from clinical trials, as …